Management of refractory rheumatoid arthritis

Reading File

Finding Sources

Searching PubMed

"Rheumatoid Arthritis"[MeSH Terms] AND refractory

Searching the Web

EULAR recommendations management difficult-to-treat rheumatoid arthritis 2025

Reading File

Reading Web Page

https://ard.eular.org/article/S0003-4967(24)20397-6/fulltext

Refractory or difficult-to-treat rheumatoid arthritis

“Refractory” RA should not mean simply persistent pain after several drugs. It generally describes active RA that has failed adequate conventional synthetic DMARD therapy and at least two biologic or targeted synthetic DMARDs with different mechanisms, with ongoing inflammatory activity and management difficulty. The current EULAR difficult-to-treat RA framework stresses confirming that inflammation is truly driving symptoms before escalating immunosuppression.

1. Reassess before labelling treatment failure

Confirm active inflammatory synovitis
- Document disease activity serially, using a consistent validated measure such as CDAI, SDAI, or DAS28.
- Perform careful tender and swollen joint counts, CRP/ESR, functional assessment, and imaging for progression.
- If the clinical picture is uncertain, ultrasound with power Doppler or MRI can help distinguish synovitis from non-inflammatory pain.
Exclude mimics and contributors to high symptom scores
- Osteoarthritis, fibromyalgia/central sensitization, tendon disease, mechanical joint damage, crystal arthritis, infection, depression, sleep disorder, obesity, and neuropathic pain.
- Inflammatory markers may be normal in active RA, but persistently high patient-reported symptoms without swollen joints or Doppler synovitis should prompt caution about switching DMARDs repeatedly.
Check whether prior therapies were adequate trials
- Correct diagnosis and phenotype.
- Sufficient dose, duration, and adherence.
- Methotrexate optimized where possible: oral dose escalation, split dosing, folate supplementation, or switch to subcutaneous methotrexate before declaring intolerance or inefficacy.
- Check access barriers, self-injection technique, adverse effects, and drug interactions.

Treat-to-target management requires regular measurement and adjustment toward remission or low disease activity, rather than relying on symptoms alone. Firestein & Kelley's Textbook of Rheumatology, p. 205-222.

2. Optimize the foundation

Methotrexate (MTX) remains the anchor drug when tolerated and is usually continued with a biologic or targeted synthetic DMARD.
If MTX cannot be used, options include leflunomide or sulfasalazine, although the choice of partner or monotherapy depends on the advanced agent selected.
Avoid chronic glucocorticoids. A short bridging course may occasionally be used for a flare, with a defined taper plan.
NSAIDs are for symptomatic relief only and do not prevent structural damage. Goldman-Cecil Medicine, p. 2794.
Use physiotherapy, occupational therapy, exercise, joint protection, smoking cessation, weight management, fatigue and sleep management, and psychological support. Multidisciplinary rheumatology care is recommended. Goldman-Cecil Medicine, p. 2794.

3. Escalate or switch disease-modifying therapy rationally

For persistent objective activity despite optimized csDMARD therapy, use a biologic DMARD or targeted synthetic DMARD, usually with MTX if feasible:

Class	Examples	Typical place in refractory disease
TNF inhibitors	adalimumab, etanercept, infliximab, certolizumab, golimumab	Initial biologic option, or sometimes a second TNF inhibitor after a reasoned first TNFi failure
IL-6 pathway inhibitors	tocilizumab, sarilumab	Strong option after TNFi failure; can be particularly useful as monotherapy when MTX is not tolerated
T-cell co-stimulation modulator	abatacept	Useful alternative mechanism, including in selected patients where infection or lung considerations influence choice
B-cell depletion	rituximab	Often considered in seropositive RA, previous lymphoproliferative disease, or selected comorbidity contexts
JAK inhibitors	tofacitinib, baricitinib, upadacitinib, filgotinib where approved	Effective oral targeted option, but patient-specific safety assessment is essential

After failure of a biologic or targeted therapy, switch to a different mechanism of action, particularly after failure of two TNF inhibitors. A second TNF inhibitor can be reasonable after one failure, especially where the first agent was stopped for intolerance, immunogenicity, or secondary loss of response rather than primary non-response. Do not combine two biologic DMARDs, or a biologic with a JAK inhibitor, because toxicity and serious infection risk increase without acceptable benefit.

The latest EULAR RA recommendations are listed by EULAR management guidance, including the 2025 update published in 2026.

4. Individualize selection by comorbidity and safety

Before starting or changing biologic/JAK treatment:

Screen for tuberculosis, hepatitis B and C, and relevant infection risks.
Update non-live vaccines, including influenza, pneumococcal, COVID-19, recombinant zoster, and age-appropriate vaccines.
Assess cardiovascular disease, venous thromboembolism risk, malignancy history, chronic lung disease, liver disease, renal impairment, pregnancy plans, and prior serious or recurrent infections.
Monitor CBC, liver enzymes, renal function, lipids where relevant, and drug-specific adverse effects.

JAK inhibitors: carefully balance benefit against risks of serious infection, herpes zoster, venous thromboembolism, major adverse cardiovascular events, and malignancy. In older patients, smokers or former long-term smokers, and people with cardiovascular disease, cancer risk factors, or VTE risk, a biologic alternative is often preferred if suitable.

5. Persistent symptoms despite multiple DMARDs

For genuine difficult-to-treat RA:

Refer to or co-manage with a rheumatologist experienced in refractory disease.
Reconfirm inflammatory activity with ultrasound/MRI where needed.
Address comorbid pain syndromes, structural joint damage, disability, mood, sleep, and adherence in parallel.
Consider therapeutic drug monitoring only in selected situations, such as suspected anti-drug antibodies or loss of response to certain monoclonal antibodies. It is not routine for all RA therapies.
Consider clinical-trial referral where accessible.
For irreversible damage, use targeted local measures: injections when appropriate, hand/foot orthoses, reconstructive or joint-replacement surgery, and rehabilitation.

A 2026 Cochrane network meta-analysis examined DMARD choices after biologic or targeted-therapy failure (PMID 42440279). Its relevance is that several classes retain efficacy after prior advanced-therapy failure, so treatment should be mechanism-based and individualized rather than viewed as “no options left.”

Practical algorithm

Persistent symptoms or high activity score
Confirm synovitis and exclude mimics/non-inflammatory pain
Verify adequate MTX/DMARD exposure, adherence, and safety
Treat to a measured target, reassessing about every 1-3 months during active disease
After inadequate response, switch or escalate to a biologic/targeted agent
After advanced-therapy failure, preferentially change mechanism of action
Manage pain, damage, comorbidities, infection prevention, rehabilitation, and patient priorities at every step

Management should be individualized by a rheumatologist, especially when recurrent infections, pregnancy, interstitial lung disease, cancer history, major cardiovascular disease, or multiple prior advanced-DMARD failures are present.

This is a shared conversation. Sign in to Orris to start your own chat.